Pharma Mar S.A.
Biopharmaceutical company developing oncology treatments from marine sources.
PHM | MC
Overview
Corporate Details
- ISIN(s):
- ES0169501022 (+1 more)
- LEI:
- 959800QWKZ45ZQC2AV58
- Country:
- Spain
- Address:
- Avenida de los Reyes 1 Polígono Industrial La Mina, 28770 Colmenar Viejo
- Website:
- https://pharmamar.com/en/
- Sector:
- Manufacturing
Description
Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-04-29 08:31 |
Pharma Mar e Immedica Pharma han suscrito un acuerdo en exclusiva para la distr…
|
Spanish | 259.3 KB | ||
| 2020-04-29 00:00 |
Motivo de la notificación: Persona con Responsabilidad de Dirección
|
Spanish | 91.4 KB | ||
| 2020-04-28 10:03 |
La Sociedad anuncia el inicio del ensayo clínico APLICOV-PC con Aplidin® para e…
|
Spanish | 94.8 KB | ||
| 2020-04-23 17:38 |
La sociedad remite nota de prensa sobre los resultados del primer trimestre de …
|
Spanish | 193.1 KB | ||
| 2020-04-22 17:42 |
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa d…
|
Spanish | 86.9 KB | ||
| 2020-04-20 14:34 |
Axesor eleva la calificación crediticia a largo plazo de Pharma Mar
|
Spanish | 29.6 KB | ||
| 2020-04-15 17:56 |
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa d…
|
Spanish | 50.6 KB | ||
| 2020-04-08 17:39 |
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa d…
|
English | 83.9 KB | ||
| 2020-04-06 17:40 |
La Sociedad remite detalle de las operaciones del Contrato de Liquidez comprend…
|
Spanish | 219.4 KB | ||
| 2020-03-25 17:42 |
La Sociedad informa que llevará a cabo un programa de recompra de acciones prop…
|
Spanish | 34.3 KB | ||
| 2020-03-13 08:30 |
La Sociedad informa sobre los resultados de los estudios in vitro de Aplidin® (…
|
Spanish | 28.0 KB | ||
| 2020-03-06 14:18 |
La Sociedad informa que su filial Genomica, S.A.U. ha obtenido en el día de hoy…
|
Spanish | 69.8 KB | ||
| 2020-03-03 14:49 |
La Sociedad informa que cuenta con un compuesto terapéutico, Aplidina, que por …
|
Spanish | 27.9 KB | ||
| 2020-03-02 13:31 |
Pharma Mar convoca rueda de prensa para mañana 3 de marzo a las 10:30 am en la …
|
Spanish | 27.2 KB | ||
| 2020-03-02 00:00 |
Motivo de la notificación: Persona con Responsabilidad de Dirección
|
Spanish | 91.4 KB |
Automate Your Workflow. Get a real-time feed of all Pharma Mar S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharma Mar S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharma Mar S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
